Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Investigation of wholebody MRI and circulating biomarkers of inflammation, cartilage and bone
metabolism in patients with spondyloarthritis treated with adalimumab. Furthermore to compare
ultrasound examination with wholebody MRI etc.
Phase:
Phase 4
Details
Lead Sponsor:
Glostrup University Hospital, Copenhagen Rigshospitalet, Denmark